



online
28-30.09.2023

9th Central European Congress
on Osteoporosis and Osteoarthritis
21st Congress
of the Polish Society of Osteoarthrology



free admission

PROGRAMME

Lectures in English

Wykłady po polsku

28 September 2023 THURSDAY

Time zone GMT +2	SESSIONS	CHAIRMAN/ SPEAKER
17.00-18.10	Session 01 Osteoporosis in times of war and epidemics	N. Grygorieva, E. Czerwinski
17.00	Fracture epidemiology. Bad and good news	C. Poiana (Romania)
17.18	Treatment of osteoporosis in a war condition	N. Grygorieva (Ukraine)
17.36	The landscape of osteoporosis after the Covid	R.K.Srivastava (India)
17.54	Discussion	
18.10-19.15	Session 02 Welcome & Opening	J-Y. Reginster, E. Czerwinski
18.15	The five-year partnership between ESCEO and WHO: How can a scientific society help WHO in its goals and missions to improve healthy aging	J-Y. Reginster (Belgium)
18.30	Bone forming agents: are they the solution to close the gap in the treatment of osteoporosis?	J-Y. Reginster (Belgium)
19.00	Discussion	

29 September 2023 FRIDAY

9.00-10.10	Session 03 Laboratory diagnosis of osteoporosis	H. Resch, R. Lorenc
9.00	Usefulness of laboratory tests in the diagnosis of osteoporosis	J. Przedlacki (PL Warszawa)
9.18	The place of bone markers in the diagnosis and treatment of osteoporosis	V. Palicka (Czech Republic)
9.36	Value of mRNA in the diagnosis of bone disease - own results	H.Resch (Austria)
9.54	Discussion	
	Break	
10.20-11.30	Session 04 Fracture risk assessment	J. Kanis, E. Czerwinski
10.20	The latest FRAX version	J. Kanis (UK)
10.38	How to define very high fracture risk in osteoporosis	E.M. Lewiecki (USA)
10.56	Trabecular Bone Score (TBS) in clinical practice	D. Hans (Switzerland)
11.14	Discussion	
	Break	

11.40-12.50	Session 05. Sponsored by Amgen Ocen ryzyka złamania w Polsce <i>Fracture risk assessment in Poland</i>	E. Czerwiński, P. Głuszko, E. Sewerynek
11.40	Aktualizacja zaleceń polskich w diagnostyce i leczeniu osteoporozy 2023 <i>Update of Polish recommendations in the diagnosis and treatment of osteoporosis 2023</i>	P. Głuszko (PL Warszawa)
11.58	Postępowanie z pacjentem z bardzo wysokim ryzykiem złamania <i>Management of a patient at a very high risk of fracture</i>	E. Sewerynek (PL Łódź)
12.16	Jak długo leczyć osteoporozę <i>How long to treat osteoporosis</i>	E. Czerwiński (PL Kraków)
12.34	Discussion	

LUNCH TIME

13.50-15.00	Session 06 For whom bone forming and for whom anti-resorptive drugs	S.E. Papapoulos, N. Harvey
13.50	Bone forming agents. State of art	S.E. Papapoulos (the Netherlands)
14.08	Bisphosphonates should be first line treatment for osteoporosis (new ACP guidelines) - pro et contra	T. Kocjan (Slovenia)
14.26	Advantages and disadvantages of bisphosphonate and denosumab therapy	N. Harvey (UK)
14.44	Discussion	

Break

15.10-16.20	Session 07 Osteoporosis in metabolic diseases	E. Franek, N. Harvey
15.10	Risk of fractures in diabetes	E. Franek (PL Warszawa)
15.28	Obesity increases or decreases fracture risk	M. Rell-Bakalarska (PL Warszawa)
15.46	Bone and atherosclerosis	N. Harvey (UK)
16.04	Discussion	

Break

16.30-17.40	Session 08 Current challenges in the treatment of osteoporosis	S. Ferrari, P. Lakatos
16.30	Avascular necrosis of the jaw during osteoporosis treatment	P. Lakatos (Hungary)
16.48	Optimal management after discontinuation of denosumab	S. Ferrari (Switzerland)
17.06	Problems of osteoporosis in women of childbearing age	P. Leszczyński (PL Poznań)
17.24	Discussion	

Break

17.50-19.45	Session 08 - B WCO-IOF-ESCEO Barcelona 2023: The most interesting lectures	M. McClung, G. Altamar Canales
17.50	Osteoporosis in aged: What we know and what we need to know?	G. Altamar Canales (Colombia)
18.08	To treat or not to treat: Continuous or intermittent therapies in osteoporosis	M. McClung (USA)
19.26	Do high and very high fracture risk really matter?	K. Javaid (UK)
18.44	Clinical effectiveness of anti-resorptives for fracture risk reduction using the Medicare database	M. Kim (USA)
19.02	Evaluating the diagnostic value of an automatic image analyses system for osteoporosis and sarcopenia in older men. MROS study	M. Imani (Australia)
19.20	Discussion	

30 September 2023 SATURDAY

9.00-10.10	Session 09 Osteoporoza u dzieci i młodzieży <i>Osteoporosis in children and adolescents</i>	D. Chlebna-Sokół, J. Konstantynowicz
9.00	Kontrowersje w diagnostyce i leczeniu chorób metabolicznych kości u dzieci <i>Controversies in the diagnosis and treatment of metabolic bone diseases in children.</i>	D. Chlebna-Sokół (PL Łódź)
9.18	Własne doświadczenia w leczeniu wrodzonej łamliwości kości u dzieci <i>Own experience in the treatment of osteogenesis imperfecta in children</i>	J. Sułko (PL Kraków)
9.36	Zdrowie szkieletowe okresu przejściowego: między dzieciństwem a dorosłością <i>Skeletal health in transitional age: between childhood and adulthood.</i>	J. Konstantynowicz (PL Białystok)
9.56	Discussion	

Break

10.20-11.30	Session 10 Sesja Polskiego Towarzystwa Ortopedycznego i Traumatologicznego. Ortopedzi dla internistów o złamaniach osteoporotycznych. <i>Session of the Polish Society of Orthopaedics and Traumatology:Orthopedists for internists about osteoporotic fractures</i>	A. Bohatyrewicz, T. Blicharski
10.20	Złamanie kręgosłupa. Cementować czy nie? <i>Spinal fracture: to cement or not?</i>	T. Blicharski (PL Lublin)
10.38	Jak zapobiegać powikłaniom po złamaniu k. promieniowej <i>How to prevent complications after radius fracture</i>	W. Glinkowski (PL Warszawa)
10.56	Postępowanie po złamaniu bkk udowej <i>Management after hip fracture</i>	A. Bohatyrewicz (PL Szczecin)
11.14	Discussion	

Break

11.40-12.50	Session 11 Falls and sarcopenia	A. Skalska, N. van der Velde
11.40	Sarcopenia. Clinical and molecular insights	A. Gasparik (Romania)
11.58	World guidelines for falls prevention and management for older adults: a global initiative	N. van der Velde (the Netherlands)
12.16	Consequences of falls	A. Skalska (PL Krakow)
12.34	Discussion	

LUNCH TIME

13.50-15.00	Session 12 Rare bone diseases	J. Konstantynowicz, A. Żyluk
13.50	Paget disease: Diagnosis and treatment	B. Jóźwiak (PL Poznan)
14.08	Osteogenesis imperfecta in adults: To treat or not to treat?	J. Konstantynowicz (PL Białystok)
14.26	Sudeck Syndrome in clinical practice	A. Żyluk (PL Szczecin)
14.44	Discussion	

Break

15.10-16.20	Session 13 Vitamin D: a new look	S. Cummings, E. Marcinowska-Suchowierska
15.10	Conclusions from modern clinical trials on vitamin D	E. Marcinowska-Suchowierska (PL Warszawa)
15.28	The place of vitamin D metabolites in the treatment of osteoporosis	W. Misiorowski (PL Warszawa)
15.46	Vitamin D supplements for fracture prevention	S. Cummings (USA)
16.04	Discussion	

Break

16.30-17.40	Session 14 Osteoporosis and aging	B. Kwiatkowska, M. Korkosz, V. Babalyan
16.30	Osteoporosis in elderly people. Causes, symptoms, treatment and prevention	V. Babalyan (Armenia)
16.48	Cardiovascular risk during osteoporosis therapy	M. Korkosz (PL Krakow)
17.06	Prophylaxis and proper treatment of metastases	E. Kalinka (PL Łódź)
17.24	Discussion	

Break

17.50-19.00

Session 15
Osteoarthritis. How to treat ?

E. Czerwiński, J. Woroń, J. Badurski

17.50	Modern standards of treatment of osteoarthritis	P. Wiland (PL Wroclaw)
18.08	Chronic analgesic treatment in patients with peptic ulcer disease	J. Woroń (PL Krakow)
18.26	What is the survival time of hip and knee endoprosthesis	G. Maalouf (Lebanon) Maroun Rizkallah
18.44	Discussion	
19.05	Closing	

Organizers



**Polish Society
of Osteoarthrology**



IAMP
INTERDISCYPLINARNA AKADEMIA
MEDYCYNY PRAKTYCZNEJ

Sponsor

AMGEN

Media patronage



healthcare
an Open Access Journal by MDPI

GAZETA
LEKARSKA

mp.pl

portal medyczny
esculap.com

ŚWIAT MEDYCYNY
I FARMACJI

v33 2023.09.26